Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Neurocrine Biosciences, Inc. (NBIX) vs Viatris Inc. (VTRS)

Neurocrine Biosciences, Inc. and Viatris Inc. are both Drug Manufacturers Specialty & Generic companies. Viatris Inc. is the larger, with a market value of $20.0B against $14.1B — 1.4× the size. Viatris Inc. has negative trailing earnings, so its P/E is not meaningful; Neurocrine Biosciences, Inc. trades at 19.6×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 4.40%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs −2.79%) and the higher return on invested capital (15.0% vs −0.20%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 15 and Viatris Inc. on 6.

Valuation

Metric NBIX VTRS Drug Manufacturers Specialty & Generic median
P/E 19.63 n/m 20.14
P/S 4.14 1.41 2.25
P/B 3.78 1.45 1.90
Price to free cash flow 16.06 10.97 16.54
EV/EBITDA 16.65 12.22 12.29
EV/Sales 4.11 2.25 2.56
Earnings yield 5.09% (2.02%) (2.99%)
Free cash flow yield 6.23% 9.11% 0.00%

Profitability

Metric NBIX VTRS Drug Manufacturers Specialty & Generic median
Gross margin 97.94% 34.83% 53.94%
Operating margin 23.56% (0.59%) 0.00%
Net margin 20.91% (2.79%) 0.00%
Free cash flow margin 25.80% 12.83% 0.00%
Return on equity 22.09% (2.75%) (0.40%)
Return on assets 15.26% (1.12%) (3.32%)
Return on invested capital 15.04% (0.20%) 0.00%

Growth

Metric NBIX VTRS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 34.42% 4.40% 10.01%
EPS growth (last fiscal year) 41.95% (466.04%) —
Revenue growth, 5-year CAGR 22.29% 3.66% 6.74%
Net income growth, 5-year CAGR 3.28% 0.00% 0.00%

Health

Metric NBIX VTRS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.94 0.05
Current ratio 1.87 1.58 2.31
Net debt to EBITDA (2.33) 4.92 0.85

Dividend

Metric NBIX VTRS Drug Manufacturers Specialty & Generic median
Dividend yield — 4.15% 1.70%
Payout ratio 0.00 0.31 0.00

Size

Metric NBIX VTRS Drug Manufacturers Specialty & Generic median
Market cap 14.12b 19.99b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack